Pulmonary fibrosis is a chronic lung disease characterized by excessive accumulation of
extracellular matrix (ECM) and remodeling of the lung architecture. Idiopathic pulmonary …

Glucocorticoids are the most effective anti‐inflammatory therapy for asthma yet are relatively
ineffective in chronic obstructive pulmonary disease. Glucocorticoids suppress inflammation …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Background Despite the availability of national and international guidelines, evidence
suggests that chronic obstructive pulmonary disease (COPD) treatment is not always …

Background QVA149 is an inhaled fixed-dose combination therapy under development for
the treatment of chronic obstructive pulmonary disease (COPD). It combines indacaterol (a …

BACKGROUND:: Systemic corticosteroids are known to increase diabetes risk, but the
effects of high-dose inhaled corticosteroids are unknown. We assessed whether the use and …

Inhaled corticosteroids (ICS) are the most effective controllers of asthma. They suppress
inflammation mainly by switching off multiple activated inflammatory genes through …

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD)
treatment strategy recommends the use of one or more bronchodilators according to the …

Background Three classes of inhaler medications are used to manage chronic obstructive
pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …